Comprehensive review of generalized anxiety disorder in primary care in Europe

References

• Hettema JM, Neale MC, Kendler KS. A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am J Psychiatry 2001;158:1568-78
   PubMed Web of Science ®Google Scholar
• Merikangas KR, Low NC. Genetic epidemiology of anxiety disorders. Handb Exp Pharmacol 2005;169:163-79
   PubMedGoogle Scholar
• Wittchen HU, Kessler RC, Beesdo K, et al. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry 2002;63(Suppl 8):24-34
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association (APA). Diagnostic Statistical Manual of Mental Disorders, 4th Ed., Text Rev. Washington DC. APA, 2000
   Google Scholar
• World Health Organization (WHO). The ICD-10 Classification of Mental and Behavioural Disorders. Clinical descriptions and diagnostic guidelines, Geneva, WHO, 1992
   Google Scholar
• Andrews G, Slade T. The classification of anxiety disorders in ICD-10 and DSM-IV: a concordance analysis. Psychopathology 2002;35:100-6
   PubMed Web of Science ®Google Scholar
• Coutinho FC, Dias GP, do Nascimento Bevilaqua MC, et al. Current concept of anxiety: implications from Darwin to the DSM-V for the diagnosis of generalized anxiety disorder. Expert Rev Neurother 2010;10:1307-20
   PubMed Web of Science ®Google Scholar
• Lewis-Fernández R, Hinton DE, Laria AJ, et al. Culture and the anxiety disorders: recommendations for DSM-V. Depress Anxiety 2010;27:212-29
   PubMed Web of Science ®Google Scholar
• Wittchen HU, Jacobi F, Rehm J, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011;21:655-79
   PubMed Web of Science ®Google Scholar
• Hoffman DL, Dukes EM, Wittchen HU. Human and economic burden of generalized anxiety disorder. Depress Anxiety 2008;25:72-90
   PubMed Web of Science ®Google Scholar
• Bobes J, Caballero L, Vilardaga I, et al. Disability and health-related quality of life in outpatients with generalised anxiety disorder treated in psychiatric clinics: is there still room for improvement? Ann Gen Psychiatry 2011;10:7
   PubMedGoogle Scholar
• Saarni SI, Suvisaari J, Sintonen H, et al. Impact of psychiatric disorders on health-related quality of life: general population survey. Br J Psychiatry 2007;190:326-32
   PubMed Web of Science ®Google Scholar
• de Wit LM, Fokkema M, van Straten A, et al. Depressive and anxiety disorders and the association with obesity, physical, and social activities. Depress Anxiety 2010;27:1057-65
   PubMed Web of Science ®Google Scholar
• Allgulander C, Jørgensen T, Wade A, et al. Health-related quality of life (HRQOL) among patients with Generalised Anxiety Disorder: evaluation conducted alongside an escitalopram relapse prevention trial. Curr Med Res Opin 2007;23:2543-9
   PubMed Web of Science ®Google Scholar
• Lieb R, Becker E, Altamura C. The epidemiology of generalized anxiety disorder in Europe. Eur Neuropsychopharmacol 2005;15:445-52
   PubMed Web of Science ®Google Scholar
• Andlin-Sobocki P, Jönsson B, Wittchen HU, et al. Cost of disorders of the brain in Europe. Eur J Neurol 2005;12(Suppl 1):1-27
   PubMed Web of Science ®Google Scholar
• Knapp M, McDaid D, Parsonage M. Mental Health Promotion and Prevention: The Economic Case. 2011. Available at: http://eprints.lse.ac.uk/32311/1/Knapp_et_al__MHPP_The_Economic_Case.pdf [Last accessed July 2011]
   Google Scholar
• No health without mental health: a cross-governmental health outcomes strategy for people of all ages. HM Government, Department of Health, 2011. Available at: http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_124058.pdf [Last accessed July 2011]
   Google Scholar
• Edwards TM, Stern A, Clarke DC, et al. The treatment of patients with medically unexplained symptoms in primary care: a review of the literature. Mental Health in Family Medicine 2010;7:209-21
   PubMedGoogle Scholar
• Romera I, Fernández-Pérez S, Montejo AL, et al. Generalized anxiety disorder, with or without co-morbid major depressive disorder, in primary care: prevalence of painful somatic symptoms, functioning and health status. J Affect Disord 2010;127:160-8
   PubMed Web of Science ®Google Scholar
• Fava GA, Porcelli P, Rafanelli C, et al. The spectrum of anxiety disorders in the medically ill. J Clin Psychiatry 2010;71:910-14
   PubMed Web of Science ®Google Scholar
• Gili M, Comas A, García-García M, et al. Comorbidity between common mental disorders and chronic somatic diseases in primary care patients. Gen Hosp Psychiatry 2010;32:240-5
   PubMed Web of Science ®Google Scholar
• Kroenke K, Spitzer RL, Williams JB, et al. The Patient Health Questionnaire Somatic, Anxiety, and Depressive Symptom Scales: a systematic review. Gen Hosp Psychiatry 2010;32:345-59
   PubMed Web of Science ®Google Scholar
• Nutt D, Argyropoulos S, Hood S, et al. Generalized anxiety disorder: a comorbid disease. Eur Neuropsychopharmacol 2006;16(Suppl 2):S109-18
   PubMedGoogle Scholar
• Lee S, Wu J, Ma YL, et al. Irritable bowel syndrome is strongly associated with generalized anxiety disorder: a community study. Aliment Pharmacol Ther 2009;30:643-51
   PubMed Web of Science ®Google Scholar
• Mussell M, Kroenke K, Spitzer RL, et al. Gastrointestinal symptoms in primary care: prevalence and association with depression and anxiety. J Psychosom Res 2008;64:605-12
   PubMed Web of Science ®Google Scholar
• Senaratne R, Van Ameringen M, Mancini C, et al. The prevalence of migraine headaches in an anxiety disorders clinic sample. CNS Neurosci Ther 2010;16:76-82
   PubMed Web of Science ®Google Scholar
• Goodwin RD. Asthma and anxiety disorders. Adv Psychosom Med 2003;24:51-71
   PubMedGoogle Scholar
• Vogelzangs N, Seldenrijk A, Beekman AT, et al. Cardiovascular disease in persons with depressive and anxiety disorders. J Affect Disord 2010;125:241-8
   PubMed Web of Science ®Google Scholar
• Grigsby AB, Anderson RJ, Freedland KE, et al. Prevalence of anxiety in adults with diabetes: a systematic review. J Psychosom Res 2002;53:1053-60
   PubMed Web of Science ®Google Scholar
• Muller JE, Koen L, Stein DJ. Anxiety and medical disorders. Curr Psychiatry Rep 2005;7:245-51
   PubMedGoogle Scholar
• Wittchen HU, Zhao S, Kessler RC, et al. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:355-64
   PubMed Web of Science ®Google Scholar
• Simon NM. Generalized anxiety disorder and psychiatric comorbidities such as depression, bipolar disorder, and substance abuse. J Clin Psychiatry 2009;70(Suppl 2):10-14
   PubMed Web of Science ®Google Scholar
• Alegría AA, Hasin DS, Nunes EV, et al. Comorbidity of generalized anxiety disorder and substance use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2010;71:1187-95; quiz 252-3
   PubMed Web of Science ®Google Scholar
• Smith JP, Book SW. Comorbidity of generalized anxiety disorder and alcohol use disorders among individuals seeking outpatient substance abuse treatment. Addict Behav 2010;35:42-5
   PubMed Web of Science ®Google Scholar
• Touchette E, Henegar A, Godart NT, et al. Subclinical eating disorders and their comorbidity with mood and anxiety disorders in adolescent girls. Psychiatry Res 2011;185:185-92
   PubMed Web of Science ®Google Scholar
• Arroll B, Kendrick T. Anxiety, in Primary Care Mental Health. L Gask, H Lester, T Kendrick, et al, London: Royal College of Psychiatrists UK, 2009:145-55
   Google Scholar
• Khouzam HR. Anxiety disorders: guidelines for effective primary care, part 1, diagnosis. Psychiatric Times 2009;49:1-3
   Google Scholar
• Spitzer RL, Kroenke K, Williams JB, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006;166:1092-7
   PubMed Web of Science ®Google Scholar
• Bjelland I, Dahl AA, Haug TT, et al. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 2002;52:69-77
   PubMed Web of Science ®Google Scholar
• Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-70
   PubMed Web of Science ®Google Scholar
• Katzman MA. Current considerations in the treatment of generalized anxiety disorder. CNS Drugs 2009;23:103-20
   PubMed Web of Science ®Google Scholar
• Rynn MA, Brawman-Mintzer O. Generalized anxiety disorder: acute and chronic treatment. CNS Spectr 2004;9:716-23
   PubMed Web of Science ®Google Scholar
• Fernandez A, Haro JM, Martinez-Alonso M, et al. Treatment adequacy for anxiety and depressive disorders in six European countries. Br J Psychiatry 2007;190:172-3
   PubMed Web of Science ®Google Scholar
• Kennerley H. The prevention of anxiety disorders. In: The Prevention of Mental Illness in Primary Care. T. Kendrick, A. Tylee, P. Freeling, eds. London: Cambridge University Press, 1996:188-206
   Google Scholar
• Roy-Byrne P, Craske MG, Sullivan G, et al. Delivery of evidence-based treatment for multiple anxiety disorders in primary care: a randomized controlled trial. JAMA 2010;303:1921-8
   PubMed Web of Science ®Google Scholar
• van Boeijen CA, van Oppen P, van Balkom AJ, et al. Treatment of anxiety disorders in primary care practice: a randomised controlled trial. Br J Gen Pract 2005;55:763-9
   PubMed Web of Science ®Google Scholar
• Allgulander C. Novel approaches to treatment of generalized anxiety disorder. Curr Opin Psychiatry 2010;23:37-42
   PubMed Web of Science ®Google Scholar
• NICE clinical guideline 113 – Generalised anxiety disorder and panic disorder (with or without agoraphobia) in adults. National Institute for Health and Clinical Excellence, 2011. Available at: http://www.nice.org.uk/nicemedia/live/13314/52599/52599.pdf [Last accessed December 2011]
   Google Scholar
• Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive–compulsive and post-traumatic stress disorders – first revision. World J Biol Psychiatry 2008;9:248-312
   PubMed Web of Science ®Google Scholar
• Craske MG, Rose RD, Lang A, et al. Computer-assisted delivery of cognitive behavioral therapy for anxiety disorders in primary-care settings. Depress Anxiety 2009;26:235-42
   PubMed Web of Science ®Google Scholar
• Hofmann SG, Smits JA. Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. J Clin Psychiatry 2008;69:621-32
   PubMed Web of Science ®Google Scholar
• Norton PJ, Price EC. A meta-analytic review of adult cognitive-behavioral treatment outcome across the anxiety disorders. J Nerv Ment Dis 2007;195:521-31
   PubMed Web of Science ®Google Scholar
• Stewart RE, Chambless DL. Cognitive–behavioral therapy for adult anxiety disorders in clinical practice: a meta-analysis of effectiveness studies. JCCP 2009;77:595-606
   Google Scholar
• Hunot V, Churchill R, Teixeira V, et al. Psychological therapies for generalised anxiety disorder. Cochrane Database Syst Rev 2007;preprintArt No. CD001848
   Google Scholar
• Covin R, Ouimet AJ, Seeds PM, et al. A meta-analysis of CBT for pathological worry among clients with GAD. J Anxiety Disord 2008;22:108-16
   PubMed Web of Science ®Google Scholar
• Hoyer J, Beesdo K, Gloster AT, et al. Worry exposure versus applied relaxation in the treatment of generalized anxiety disorder. Psychother Psychosom 2009;78:106-15
   PubMed Web of Science ®Google Scholar
• Dugas MJ, Brillon P, Savard P, et al. A randomized clinical trial of cognitive–behavioral therapy and applied relaxation for adults with generalized anxiety disorder. Behav Ther 2010;41:46-58
   PubMed Web of Science ®Google Scholar
• Hofmann SG, Sawyer AT, Witt AA, et al. The effect of mindfulness-based therapy on anxiety and depression: a meta-analytic review. JCCP 2010;78:169-83
   Google Scholar
• Marchand WR. Mindfulness-based stress reduction, mindfulness-based cognitive therapy, and Zen meditation for depression, anxiety, pain, and psychological distress. J Psychiatric Practice 2012;18:233-52
   PubMed Web of Science ®Google Scholar
• Lee KC, Feldman MD, Finley PR. Cover article part 1 of 2. Beyond depression: evaluation of newer indications and off-label uses for SSRIs. Formulary 2002;37:240-51
   Web of Science ®Google Scholar
• Baldwin D, Woods R, Lawson R, et al. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. BMJ 2011;342:d1199
   PubMed Web of Science ®Google Scholar
• Hidalgo RB, Tupler LA, Davidson JR. An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J Psychopharmacol 2007;21:864-72
   PubMed Web of Science ®Google Scholar
• Kapczinski F, Lima MS, Souza JS, et al. Antidepressants for generalized anxiety disorder. Cochrane Database Syst Rev 2003;preprintArt No. CD003592
   Google Scholar
• Boschen MJ. A meta-analysis of the efficacy of pregabalin in the treatment of generalized anxiety disorder. Can J Psychiatry 2011;56:558-66
   PubMed Web of Science ®Google Scholar
• Chessick CA, Allen MH, Thase M, et al. Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev 2006;3:CD006115
   Google Scholar
• Martin JL, Sainz-Pardo M, Furukawa TA, et al. Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials. J Psychopharmacol 2007;21:774-82
   PubMed Web of Science ®Google Scholar
• Guaiana G, Barbui C, Cipriani A. Hydroxyzine for generalised anxiety disorder. Cochrane Database Syst Rev 2010;preprintArt No. CD006815
   Google Scholar
• Depping AM, Komossa K, Kissling W, et al. Second-generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev 2010;preprintArt No. CD008120
   Google Scholar
• Gao K, Kemp DE, Fein E, et al. Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics. J Clin Psychiatry 2011;72:1063-71
   PubMed Web of Science ®Google Scholar
• LaLonde CD, Van Lieshout RJ. Treating generalized anxiety disorder with second generation antipsychotics: a systematic review and meta-analysis. J Clin Psychopharmacol 2011;31:326-33
   PubMed Web of Science ®Google Scholar
• Maher AR, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 2011;306:1359-69
   PubMed Web of Science ®Google Scholar
• Davidson JR, Bose A, Korotzer A, et al. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress Anxiety 2004;19:234-40
   PubMed Web of Science ®Google Scholar
• Goodman WK, Bose A, Wang Q. Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J Affect Disord 2005;87:161-7
   PubMed Web of Science ®Google Scholar
• Summary of Product Characteristics: Paroxetine 20mg tablets. Actavis UK Ltd, 2011. Available at: http://www.medicines.org.uk/emc/medicine/24065/SPC/ [Last accessed September 2011]
   Google Scholar
• Summary of Product Characteristics: Prozac 20mg hard capsules, and 20mg per 5ml oral liquid. Eli Lilly and Company Limited, 2011. Available at: http://www.medicines.org.uk/emc/medicine/504/SPC/ [Last accessed September]
   Google Scholar
• Summary of Product Characteristics: Cipralex 5, 10 and 20 mg film-coated tablets and 20 mg/ml oral drops, solution. Lundbeck Limited, 2011. Available at: http://www.medicines.org.uk/emc/medicine/21976/SPC/ [Last accessed September 2011]
   Google Scholar
• Summary of Product Characteristics: Cipramil tablets. Lundbeck Limited, 2011. Available at: http://www.medicines.org.uk/emc/medicine/1070/SPC/ [Last accessed September 2011]
   Google Scholar
• Summary of Product Characteristics: Lustral. Pfizer Limited, 2011. Available at: http://www.medicines.org.uk/emc/medicine/1467/SPC/ [Last accessed September 2011]
   Google Scholar
• Yuan Y, Tsoi K, Hunt RH. Selective serotonin reuptake inhibitors and risk of upper GI bleeding: confusion or confounding? Am J Med 2006;119:719-27
   PubMed Web of Science ®Google Scholar
• Song HR, Wang HR, Jung YE, et al. The change of platelet counts after administrations of escitalopram, fluoxetine, paroxetine, venlafaxine, mirtazapine, bupropion in depressive patients. Presented at WPA Thematic Conference 2011, Istanbul, Turkey
   Google Scholar
• Bielski RJ, Bose A, Chang CC. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry 2005;17:65-9
   PubMedGoogle Scholar
• Allgulander C, Hartford J, Russell J, et al. Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trials. Curr Med Res Opin 2007;23:1245-52
   PubMed Web of Science ®Google Scholar
• Carter NJ, McCormack PL. Duloxetine: a review of its use in the treatment of generalized anxiety disorder. CNS Drugs 2009;23:523-41
   PubMed Web of Science ®Google Scholar
• Rynn M, Russell J, Erickson J, et al. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety 2008;25:182-9
   PubMed Web of Science ®Google Scholar
• Allgulander C, Nutt D, Detke M, et al. A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder. J Psychopharmacol 2008;22:417-25
   PubMed Web of Science ®Google Scholar
• Beesdo K, Hartford J, Russell J, et al. The short- and long-term effect of duloxetine on painful physical symptoms in patients with generalized anxiety disorder: results from three clinical trials. J Anxiety Disord 2009;23:1064-71
   PubMed Web of Science ®Google Scholar
• Nicolini H, Bakish D, Duenas H, et al. Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial. Psychol Med 2009;39:267-76
   PubMed Web of Science ®Google Scholar
• Endicott J, Russell JM, Raskin J, et al. Duloxetine treatment for role functioning improvement in generalized anxiety disorder: three independent studies. J Clin Psychiatry 2007;68:518-24
   PubMed Web of Science ®Google Scholar
• Summary of Product Characteristics: Cymbalta 30 mg hard gastro-resistant capsules, Cymbalta 60 mg hard gastro-resistant capsules. Eli Lilly and Company Limited, 2011. Available at: http://www.medicines.org.uk/emc/medicine/15694/SPC/ [Last accessed September 2011]
   Google Scholar
• Summary of Product Characteristics: Efexor XL. Wyeth Pharmaceuticals, 2011. Available at: http://www.medicines.org.uk/emc/medicine/2210/SPC/ [Last accessed September 2011]
   Google Scholar
• Katzman M. Venlafaxine in the treatment of anxiety disorders. Expert Rev Neurother 2004;4:371-81
   PubMedGoogle Scholar
• Summary of Product Characteristics: Imipramine tablets 10mg. Actavis UK Ltd, 2011. Available at: http://www.medicines.org.uk/emc/medicine/23977/SPC/ [Last accessed September 2011]
   Google Scholar
• Nutt DJ. Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectr 2005;10:49-56
   PubMed Web of Science ®Google Scholar
• Kavoussi R. Pregabalin: from molecule to medicine. Eur Neuropsychopharmacol 2006;16(Suppl 2):S128-33
   PubMed Web of Science ®Google Scholar
• Kasper S, Herman B, Nivoli G, et al. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int Clin Psychopharmacol 2009;24:87-96
   PubMed Web of Science ®Google Scholar
• Summary of Product Characteristics: Lyrica capsules. Pfizer Limited, 2011. Available at: http://www.medicines.org.uk/emc/medicine/14651/SPC/ [Last accessed September 2011]
   Google Scholar
• Cabrera J, Emir B, Dills D, et al. Characterizing and understanding body weight patterns in patients treated with pregabalin. Curr Med Res Opin 2012;28:1027-37
   PubMed Web of Science ®Google Scholar
• Pollack MH, Tiller J, Xie F, et al. Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies. J Clin Psychopharmacol 2008;28:308-16
   PubMed Web of Science ®Google Scholar
• Pollack MH, Roy-Byrne PP, Van Ameringen M, et al. The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study. J Clin Psychiatry 2005;66:1401-8
   PubMed Web of Science ®Google Scholar
• Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. N Engl J Med 1993;328:1398-405
   PubMed Web of Science ®Google Scholar
• Summary of Product Characteristics; Chlordiazepoxide 10mg Capsules. Kent Pharmaceuticals Ltd, 2012. Available at: http://www.medicines.org.uk/EMC/medicine/26299/SPC/Chlordiazepoxide+10mg+Capsules/#PRODUCTINFO [Last accessed September 2012]
   Google Scholar
• Longo LP, Johnson B. Addiction: Part I. Benzodiazepines – side effects, abuse risk and alternatives. Am Fam Physician 2000;61:2121-8
   PubMed Web of Science ®Google Scholar
• Summary of Product Characteristics: Buspirone 10mg tablets. Actavis UK Ltd, 2011. Available at: http://www.medicines.org.uk/emc/medicine/23859/SPC/ [Last accessed September 2011]
   Google Scholar
• Llorca PM, Spadone C, Sol O, et al. Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study. J Clin Psychiatry 2002;63:1020-7
   PubMed Web of Science ®Google Scholar
• Summary of Product Characteristics: Atarax 10mg. Alliance Pharmaceuticals, 2011. Available at: http://www.medicines.org.uk/emc/medicine/20061/SPC/ [Last accessed September 2011]
   Google Scholar
• Summary of Product Characterics: Seroquel 25 mg, 100 mg, 150 mg, 200 mg, 300 mg film-coated tablets. AstraZeneca UK Limited, 2012. Available at: http://www.medicines.org.uk/emc/medicine/2295/SPC/ [Last accessed August 2012]
   Google Scholar
• Merideth C, Cutler AJ, She F, et al. Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study. Int Clin Psychopharmacol 2012;27:40-54
   PubMed Web of Science ®Google Scholar
• Bandelow B, Chouinard G, Bobes J, et al. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol 2010;13:305-20
   PubMed Web of Science ®Google Scholar
• Katzman MA, Brawman-Mintzer O, Reyes EB, et al. Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial. Int Clin Psychopharmacol 2011;26:11-24
   PubMed Web of Science ®Google Scholar
• Stein DJ, Andersen HF, Goodman WK. Escitalopram for the treatment of GAD: efficacy across different subgroups and outcomes. Ann Clin Psychiatry 2005;17:71-5
   PubMedGoogle Scholar
• Steiner M, Allgulander C, Ravindran A, et al. Gender differences in clinical presentation and response to sertraline treatment of generalized anxiety disorder. Hum Psychopharmacol 2005;20:3-13
   PubMed Web of Science ®Google Scholar
• Pollack MH, Endicott J, Liebowitz M, et al. Examining quality of life in patients with generalized anxiety disorder: clinical relevance and response to duloxetine treatment. J Psychiatr Res 2008;42:1042-9
   PubMed Web of Science ®Google Scholar
• Ninan PT. New insights into the diagnosis and pharmacologic management of generalized anxiety disorder. Psychopharmacol Bull 2002;36:105-22
   PubMedGoogle Scholar
• Rickels K, Etemad B, Khalid-Khan S, et al. Time to relapse after 6 and 12 months’ treatment of generalized anxiety disorder with venlafaxine extended release. Arch Gen Psychiatry 2010;67:1274-81
   PubMed Web of Science ®Google Scholar
• Donovan MR, Glue P, Kolluri S, et al. Comparative efficacy of antidepressants in preventing relapse in anxiety disorders – a meta-analysis. J Affect Disord 2010;123:9-16
   PubMed Web of Science ®Google Scholar
• Feltner D, Wittchen HU, Kavoussi R, et al. Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol 2008;23:18-28
   PubMed Web of Science ®Google Scholar